Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04, Briefing.com reports. The company had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 3,072.86% and a negative net margin of 150.74%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business earned ($0.36) EPS.

Shares of Nektar Therapeutics (NASDAQ:NKTR) opened at 19.64 on Wednesday. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $24.88. The company has a 50-day moving average of $20.53 and a 200 day moving average of $18.09. The firm’s market cap is $3.05 billion.

Several analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a research report on Monday. They set a “buy” rating and a $31.00 price objective for the company. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Jefferies Group LLC set a $25.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Saturday, April 22nd. Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, August 1st. Finally, Roth Capital set a $31.00 price objective on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 22nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $26.56.

TRADEMARK VIOLATION WARNING: “Nektar Therapeutics (NKTR) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/nektar-therapeutics-nasdaqnktr-issues-earnings-results-misses-expectations-by-0-03-eps.html.

In related news, SVP Ivan P. Gergel sold 54,920 shares of the stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total transaction of $1,158,812.00. Following the sale, the senior vice president now directly owns 98,492 shares of the company’s stock, valued at $2,078,181.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Chess sold 5,000 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $19.79, for a total value of $98,950.00. Following the sale, the director now directly owns 276,623 shares in the company, valued at $5,474,369.17. The disclosure for this sale can be found here. Insiders have sold 159,803 shares of company stock worth $3,328,247 over the last ninety days. 5.44% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Nektar Therapeutics by 180,432.9% in the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock valued at $470,234,000 after buying an additional 20,024,448 shares during the period. Vanguard Group Inc. boosted its stake in Nektar Therapeutics by 4.9% in the first quarter. Vanguard Group Inc. now owns 13,607,980 shares of the biopharmaceutical company’s stock valued at $319,379,000 after buying an additional 634,700 shares during the period. First Trust Advisors LP boosted its stake in Nektar Therapeutics by 8.0% in the first quarter. First Trust Advisors LP now owns 2,249,950 shares of the biopharmaceutical company’s stock valued at $52,806,000 after buying an additional 166,521 shares during the period. Bank of New York Mellon Corp boosted its stake in Nektar Therapeutics by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock valued at $41,812,000 after buying an additional 12,730 shares during the period. Finally, FMR LLC boosted its stake in Nektar Therapeutics by 42.4% in the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock valued at $45,711,000 after buying an additional 580,341 shares during the period. 94.09% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.